# Spinal Myoclonus in Subacute Combined Degeneration Caused by Nitrous Oxide Intoxication

Mei-Shian Wu<sup>1,2</sup>, Yaw-Don Hsu<sup>1</sup>, Jiann-Chyun Lin<sup>1</sup>, Shih-Cheng Chen<sup>1,3</sup>, and Jiunn-Tay Lee<sup>1</sup>

Abstract- A 26-year-old patient developed ascending weakness and paresthesias. Megaloblastic anemia and mildly reduced serum vitamin B<sub>12</sub> (B<sub>12</sub>) concentration were noted. Myoclonus-like muscular contractions appeared over four extremities and in the trunk. She admitted inhaling nitrous oxide (N<sub>2</sub>O) as a euphoriant repeatedly at party. Following parenteral B<sub>12</sub> administration, her neurological deficit promptly resolved. This case demonstrated the abuse of N<sub>2</sub>OI is an important cause of subacute combined degeneration (SCD) of the spinal cord. To our knowledge, this is the first report of involuntary movements in a patient with N<sub>2</sub>O intoxication. Although the mechanism remains unknown, involuntary movements similar to myoclonus should be considered as one of the extraordinary neurological manifestations of N<sub>2</sub>O intoxication.

Key Words: Subacute combined degeneration (SCD), Nitrous oxide (N<sub>2</sub>O), Magnetic resonance imaging (MRI), Myoclonus, Vitamin B<sub>12</sub>

Acta Neurol Taiwan 2007;16:102-105

### INTRODUCTION

Nitrous oxide (N<sub>2</sub>O) abuse is relatively common<sup>(1,2)</sup> and may cause significant neurological disability resulting from vitamin  $B_{12}$  ( $B_{12}$ ) deficiency. Subacute combined degeneration (SCD) of the spinal cord is a result of  $B_{12}$  deficiency and characterized by weakness, abnormal sensations, mental problems and visual difficulties<sup>(3,4)</sup>. Common causes of  $B_{12}$  deficiency are pernicious anemia, tropical sprue and gastric resection. SCD rarely caused by N<sub>2</sub>O intoxication. The mechanism of N<sub>2</sub>O neurotoxicity is interference with  $B_{12}$  bioavailability<sup>(5)</sup> and the resulting neurological syndromes are indistinguishable from  $B_{12}$  deficiency due to malabsorption or low dietary intake<sup>(6-8)</sup>. However a movement disorder is not a characteristic feature of N<sub>2</sub>O neurotoxicity.

Diagnosing N<sub>2</sub>O-induced neurologic disease may be difficulty if the affected patient does not disclose her inhalation activity, or the examiner fails to inquire about it. In this issue we report a rare case of spinal myoclo-

From the <sup>1</sup>Department of Neurology, Tri-Service General Hospital, National Defense Medical Center, Taipei; <sup>2</sup>Division of Neurology, Department of Internal Medicine, Chung Shan Hospital, Taipei; <sup>3</sup>Division of Neurology, Department of Internal Medicine, Chi Mei Foundation Hospital, Liouying, Taiwan.

Received July 26, 2006. Revised September 8, 2006. Accepted December 29, 2006.

Reprint requests and correspondence to: Jiunn-Tay Lee, MD. Department of Neurology, Tri-Service General Hospital, No. 325, Sec. 2, Cheng-Kung Road, Taipei, Taiwan. E-mail: jiunntay@ms26.hinet.net nus presenting SCD patient caused by N<sub>2</sub>O.

### **CASE REPORT**

A 26-year-old woman suffered from weakness and numbness of both lower limbs for 2 days. She was previously healthy and denied history of abuse of toxic substances or illegal drugs. There was no history of gastrointestinal disease or deficient intake of B<sub>12</sub>.

On neurological examination, her mental status, speech, and cranial nerves were normal. Strength was 3/5 in the lower limbs and 4/5 in the upper limbs. The tendon reflexes were absent and the plantar responses were bilaterally flexor. Sensory examination showed paresthesias in the hands and feet with markedly decreased vibratory sensation in her feet and legs following a distal-accentuating pattern.

On the 2nd hospital day, she further developed respiratory difficulty. She was initially diagnosed as Guillain-Barré syndrome (GBS). Plasma exchange was done but her symptoms did not improve. Results of the CSF studies were normal without evidence of albuminocytological dissociation (protein: 32 mg/dl, glucose: 58 mg/dl, chloride: 128 mmol/L). The anti-HCV, anti-HIV, Venereal Disease Research Laboratory test (VDRL) and thyroid function test were unremarkable. The NCV and EMG studies disclosed sensory-motor demyelinating polyneuropathy. Blood biochemistry tests and blood cell counts revealed no abnormalities except higher MCV (101.8 fL). The B<sub>12</sub> level (normal value  $\geq$  211 pg/ml) was low (187 pg/ml). She was prescribed intramuscular B<sub>12</sub> injections with a 1000  $\mu$ g daily for 7 days then 1000  $\mu$ g every week for 2 months under the impression of B<sub>12</sub> deficiency. The next day after B<sub>12</sub> injection, she developed multifocal, jerky movements over four extremities and in the trunk asynchronously. The brief and rapid twitching of muscle groups persisted during sleep with a lesser severity. The severity of myoclonic movements increased in the first four days, then they ceased spontaneously after the 7th day of B12 therapy when the dose was reduced to 1000 µg per week. EEG did not reveal any abnormality. Further electrophysiological examination could not be performed, because the patient refused investigation. When reviewing her history again, she disclosed a history of weekly N<sub>2</sub>O inhalation for 2-3 months due to recreational purpose. The MRI of cervical spine revealed abnormal demyelinating lesion affecting the posterior column between C2 and C7 spine on T2weighted images (Fig.). N<sub>2</sub>O intoxication was finally diagnosed. Her symptoms completely resolved within 2 months after B12 supplementation.




Figure. MR findings in a 26-year-old woman with a history of N₂O abuse presented with limb weakness, numbness and spinal myoclonus. (A) T2-weighted sagittal image shows increased signal intensity (black arrow) in the cervical spinal cord between C2 and C7. (B) T2-weighted axial image shows that the abnormal signal involves preferentially the posterior columns at the C4 level.

#### DISCUSSION

Under normal conditions,  $B_{12}$  is converted in the cell cytoplasm to its active form, methylcobalamin, and bound as a cofactor to the enzyme methionine synthase, catalyzing the methylation of homocysteine to methionine. The products of this reaction are essential to the biosynthesis of myelin sheath protein, DNA, carbohydrate, and lipids<sup>(9)</sup>.

N<sub>2</sub>O irreversibly inactivates methylcobalamin by oxidizing from its active constituent cobalt molecule (Co<sup>+</sup>) to the Co<sup>++</sup> and Co<sup>+++</sup> forms<sup>(10)</sup>. As methylcobalamin is depleted by N<sub>2</sub>O, levels of methionine diminish and myelination cannot be maintained, leading to symptoms and signs of SCD. The etiologies of SCD include pernicious anemia (78.3%), tropical sprue (5.6%), gastric resection (4.2%), ileal resection (2.5%), jejunal diverticula (2.1%), dietary  $B_{12}$  malabsorption (2.1%), multiple etiologies (2.8%), and etiology unknown  $(2.1\%)^{(3)}$ . N<sub>2</sub>O neurotoxicity should be recognized as an important cause of SCD. In patients with N2O neurotoxicity, the posterior columns are involved<sup>(5)</sup> with loss of position and vibration senses, ataxia, broad-based gait, and, occasionally, Lhermitte sign. The corticospinal tracts may also be involved<sup>(5)</sup>, leading to weakness, spasticity, urinary and fecal incontinence, hyperreflexia, clonus, and extensor plantar response. Peripheral neuropathy as evidenced by axonal degeneration with or without demyelination in peripheral nerves is also seen<sup>(10)</sup>.

The patient was initially diagnosed of GBS due to ascending paralysis with respiratory difficulty, lower motor neuron signs (diminished DTR) and concealed history of N<sub>2</sub>O abuse. The presence of N<sub>2</sub>O abuse with myoclonus, abnormal nerve conductions and MRI of C spine, higher MCV, and low serum B<sub>12</sub> level confirmed the diagnosis. The patient in this report presented with paresthesias, profound loss of vibratory sensation ("large fiber" sensory loss) and preservation of pain and temperature ("small fiber" function). This clinical pattern also suggests that the dysfunction of the posterior column is due to N<sub>2</sub>O neurotoxicity.

To our knowledge, there is no reported patient with

involuntary movements associated with  $N_2O$  intoxication. No sustained abnormal posture was observed in our patient, which might have suggested that the muscle contractions were part of a dystonic syndrome. They were multifocal, irregular, jerky movements and exaggerated with various stimuli, so were thought to be myoclonus.

Myoclonus can be classified into three groups, i.e. cortical, subcortical and spinal, based on the underlying physiological mechanism<sup>(11)</sup>. The normal EEG did not favor cortical myoclonus in our patient. Subcortical myoclonus does not persist during sleep, except palatal myoclonus<sup>(12)</sup>. The persistence of myoclonus during sleep is a feature of spinal myoclonus<sup>(13)</sup>. Spinal myoclonus includes two types: first simple spinal segmental myoclonus, with focal repetitive rhythmic jerks and second propriospinal myoclonus with predominantly axial, arrhythmic flexor or extensor jerks involving many spinal segments<sup>(13)</sup>. In our opinion, the irregular, asymmetric extensor and flexor jerks persisting in sleep, developing on the basis of myelopathy in our patient resembled propriospinal myoclonus.

We propose the involuntary movements were related to  $B_{12}$  therapy, because the involuntary movements happened on the next day after  $B_{12}$  supplementation. There are a few reports of therapy-induced myoclonus in the patients with  $B_{12}$  deficiency<sup>(14-16)</sup>. After a period of severe shortage of  $B_{12}$  depleted by N<sub>2</sub>O, the sudden availability of  $B_{12}$  may have resulted in a temporary imbalance of the complicated metabolic pathways of cobalamin<sup>(14,15)</sup>.

Treatment for B<sub>12</sub> deficiency and N<sub>2</sub>O toxicity is cobalamin and possibly methionine supplementation<sup>(17,18)</sup>. Parenteral vitamin therapy aimed at replenishing the total body pool is needed. Since most symptoms improve but do not resolve completely, early diagnosis and treatment are important.

In conclusion, N<sub>2</sub>O interacts with vitamin B<sub>12</sub> resulting in selective inhibition of methionine synthase, a key enzyme in methionine metabolism. As methylcobalamin is depleted by N<sub>2</sub>O, levels of methionine diminish and myelination cannot be maintained, leading to symptoms of SCD. N<sub>2</sub>O intoxication should be recognized as one of the causes of SCD if no history of vegetarian or gastric operation exists. N<sub>2</sub>O intoxication should be considered in the differential diagnosis of acute ascending paralysis. Finally, spinal myoclonus can occur in patients with N<sub>2</sub>O intoxication especially after the initiation of  $B_{12}$  treatment. The pathogenic mechanism and the nature of the movement disorder are still not clear.

## REFERENCES

- Sahenk Z, Mendell JR, Couri D, et al. Polyneuropathy from inhalation of N<sub>2</sub>O cartridges through a whipped-cream dispenser. Neurology 1978;28:485-7.
- Brett A. Myeloneuropathy from whipped cream bulbs presenting as conversion disorder. Aust N Z J Psychiatry 1997; 31:131-2.
- 3. Healton EB, Savage DG, Brust JC, et al. Neurologic aspects of cobalamin deficiency. Medicine (Baltimore) 1991;70:229-45.
- Metz J. Cobalamin deficiency and the pathogenesis of nervous system disease. Annu Rev Nutr 1992;12:59-79.
- Green R, Kinsella LJ. Current concepts in the diagnosis of cobalamin deficiency. Neurology 1995;45:1435-40.
- Blanco G, Peters HA. Myeloneuropathy and macrocytosis associated with nitrous oxide abuse. Arch Neurol 1983; 40:416-8.
- Marie RM, Le Biez E, Busson P, et al. Nitrous oxide anesthesia-associated myelopathy. Arch Neurol 2000;57:380-2.
- Kinsella LJ, Green R. 'Anesthesia paresthetica': nitrous oxide-induced cobalamin deficiency. Neurology 1995;

45:1608-10.

- Ahn SC, Brown AW. Cobalamin deficiency and subacute combined degeneration after nitrous oxide anesthesia: a case report. Arch Phys Med Rehabil 2005;86:150-3.
- Pema PJ, Horak HA, Wyatt RH. Myelopathy caused by nitrous oxide toxicity. AJNR Am J Neuroradiol 1998;19: 894-6.
- Shibasaki H. Electrophysiological studies of myoclonus. Muscle Nerve 2000;23:321-35.
- Blindauer K. Myoclonus and its disorders. Neurol Clin 2001;19:723-34.
- Brown P, Thompson PD, Rothwell JC, et al. Axial myoclonus of propriospinal origin. Brain 1991;114:197-214.
- Grattan-Smith PJ, Wilcken B, Procopis PG, et al. The neurological syndrome of infantile cobalamin deficiency: developmental regression and involuntary movements. Mov Disord 1997;12:39-46.
- Ozer EA, Turker M, Bakiler AR, et al. Involuntary movements in infantile cobalamin deficiency appearing after treatment. Pediatr Neurol 2001;25:81-3.
- Celik M, Barkut IK, Oncel C, et al. Involuntary movements associated with vitamin B12 deficiency. Parkinsonism Relat Disord 2003;10:55-7.
- 17. Yagiela JA. Health hazards and nitrous oxide: a time for reappraisal. Anesth Prog 1991;38:1-11.
- Louis-Ferdinand RT. Myelotoxic, neurotoxic and reproductive adverse effects of nitrous oxide. Adverse Drug React Toxicol Rev 1994;13:193-206.